keyword
https://read.qxmd.com/read/36401435/anemia-an-initial-manifestation-of-bing-neel-syndrome-a-case-report
#1
JOURNAL ARTICLE
Xiaoqian Yang, Zonglei Chong, Congcong Ma, Guifang Wang, Chunxia Yan
RATIONALE: It is very likely that we will miss Bing-Neel syndrome (BNS) when its initial sign is anemia.Patient concerns: A 59-year-old woman presented with episodic loss of consciousness, anemia, and extremity muscle strength scores (5-) and extremity tendon reflexes (++). DIAGNOSES: Magnetic Resonance Imaging (MRI) showed abnormal signal in the left hippocampus, left insula, and right occipital lobe. Quantitative serum immunoglobulins showed elevated immunoglobulinm (IgM) (60...
November 18, 2022: Medicine (Baltimore)
https://read.qxmd.com/read/36164109/ibcl-349-veterans-with-agent-orange-exposure-have-a-shorter-latency-from-exposure-to-diagnosis-of-indolent-b-cell-lymphoid-malignancies-compared-to-unexposed-veterans
#2
JOURNAL ARTICLE
Helen Ma, Joni Ricks-Oddie, Pankaj Gupta, Susan O'Brien, Wendy Cozen
CONTEXT: There is an increased risk of developing lymphomas after Agent Orange (AO) exposure, but specific information on lymphoma subsets is lacking. OBJECTIVE: To identify differences in latency and outcomes among Veterans with AO exposure who develop indolent B-cell lymphoid malignancies (IBCL) compared with unexposed Veterans during the same period of military enlistment. DESIGN: Retrospective case-case study Setting: National Veteran Health Administration Patients: Veterans with IBCL who served between January 1962 and May 1975...
October 2022: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/35537114/the-landscape-of-immunoglobulin-heavy-chain-gene-repertoire-and-its-clinical-relevance-in-lpl-wm
#3
JOURNAL ARTICLE
Jun Wang, Yuting Yan, Wenjie Xiong, Ge Song, Yi Wang, Jiawei Zhao, Yujiao Jia, Chengwen Li, Zhen Yu, Ying Yu, Jiawen Chen, Yang Jiao, Tingyu Wang, Rui Lyu, Qinghua Li, Yueshen Ma, Wei Liu, Dehui Zou, Gang An, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Lugui Qiu, Shuhua Yi
Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) is a heterogeneous disease in which the role of immunoglobulin heavy chain genes (IGH) remains unknown. To determine the clinical relevance of the IGH repertoire in LPL/WM patients, we performed immunoglobulin gene rearrangement and complementarity determining region 3 (CDR3) analysis. The IGH variable gene repertoire was remarkably biased in LPL/WM. IGHV3-23, IGHV4-34, IGHV3-30, IGHV3-7, and IGHV3-74 accounted for half of the cohorts' repertoire...
May 10, 2022: Blood Advances
https://read.qxmd.com/read/34993124/unexpected-discovery-of-prostatic-diffuse-large-b-cell-lymphoma-after-thulium-laser-vaporization-in-a-patient-with-waldenstrom-macroglobulinemia
#4
JOURNAL ARTICLE
Jialei Wang, Huilei Yan, Shuyan Tian, Lei Qin, Yunbo Ma
No abstract text is available yet for this article.
January 2022: Quantitative Imaging in Medicine and Surgery
https://read.qxmd.com/read/34380643/single-agent-ibrutinib-for-rituximab-refractory-waldenstr%C3%A3-m-macroglobulinemia-final-analysis-of-the-substudy-of-the-phase-iii-innovate-tm-trial
#5
JOURNAL ARTICLE
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V Matous, David MacDonald, Constantine S Tam, Olivier Tournilhac, Shuo Ma, Steven P Treon, Albert Oriol, Jerry Ping, Eva M Briso, Israel Arango-Hisijara, Meletios A Dimopoulos
PURPOSE: The first report from the open-label substudy of the phase III iNNOVATE study (PCYC-1127; NCT02165397) demonstrated that single-agent ibrutinib was efficacious and well tolerated in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia. Results from the final analysis are now reported. PATIENTS AND METHODS: Ibrutinib 420 mg was administered once daily to patients ( N = 31) who failed to achieve at least a minor response (MR) or who relapsed <12 months after their last rituximab-containing therapy...
November 1, 2021: Clinical Cancer Research
https://read.qxmd.com/read/33980914/a-comprehensive-retrospective-cohort-study-of-the-journey-of-b-cell-lymphoma-in-taiwan
#6
JOURNAL ARTICLE
Sung-Nan Pei, Ming-Chung Wang, Ming-Chun Ma, Ching-Yuan Kuo, Chun-Kai Liao, Hong Qiu, Lee Anne Rothwell, Yanfang Liu
Complete disease journey and risk factors for poor outcomes are needed to facilitate effectiveness evaluations of new therapies and clinical decision-making in B-cell Non-Hodgkin lymphoma (B-NHL), particularly in Asia where such data are lacking. This retrospective cohort study used electronic medical records from a regional medical centre in southern Taiwan to follow-up 441 patients newly diagnosed with common B-NHL subtypes: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), and Waldenström macroglobulinemia (WM), between 01-Jan-2008 and 31-Dec-2013, until 31-Dec-2017...
May 12, 2021: Scientific Reports
https://read.qxmd.com/read/33121225/a-promising-new-therapy-of-oral-ixazomib-without-rituximab-for-waldenstrom-macroglobulinemia
#7
LETTER
Wanlu Ma, Jiawei Zhao, Lu Zhang
No abstract text is available yet for this article.
February 25, 2021: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://read.qxmd.com/read/27956157/ibrutinib-for-patients-with-rituximab-refractory-waldenstr%C3%A3-m-s-macroglobulinaemia-innovate-an-open-label-substudy-of-an-international-multicentre-phase-3-trial
#8
MULTICENTER STUDY
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske
BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease. METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenström's macroglobulinaemia, refractory to rituximab and requiring treatment...
February 2017: Lancet Oncology
https://read.qxmd.com/read/27587252/-acquired-von-willebrand-syndrome-in-three-patients-and-literature-review
#9
REVIEW
H Y Ouyang, Z J Yu, J Yin, X J Zhao, Z Y Wang, W Zhang, Z N Ma, J Su, X Bai, C G Ruan
OBJECTIVE: To deepen the understanding of acquired von Willebrand syndrome (AVWS). METHODS: The clinical data of 3 patients were analyzed and related literature were reviewed. RESULTS: ① Case 1, a 70- year- old male, diagnosed as Waldenstrom macroglobulinemia and AVWS, was presented with spontaneous epitaxis and bruising. The VWF∶Ag level was 16%. Treatment was initiated with VWF concentrates. Two cycles of chemotherapy with Bortezomib, thalidomide and Dexamethasone were followed...
August 14, 2016: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/27092282/refractory-igg-warm-autoimmune-hemolytic-anemia-treated-with-eculizumab-a-novel-application-of-anticomplement-therapy
#10
JOURNAL ARTICLE
Kim Ma, Stephen Caplan
Warm autoimmune hemolytic anemia (wAIHA) is the most common form of AIHA, with corticosteroids in first-line treatment resulting in a 60-80% response rate. Atypical wAIHA and IgG plus complement mediated disease have a higher treatment failure rate and higher recurrence rate. We report a case of severe wAIHA secondary to Waldenström macroglobulinemia with life threatening intravascular hemolysis refractory to prednisone, rituximab, splenectomy, and plasmapheresis. A four-week treatment of eculizumab in this heavily pretreated patient resulted in a sustained increase in hemoglobin and transfusion independence, suggesting a role for complement inhibition in refractory wAIHA...
2016: Case Reports in Hematology
https://read.qxmd.com/read/26903547/exome-sequencing-reveals-recurrent-germ-line-variants-in-patients-with-familial-waldenstr%C3%A3-m-macroglobulinemia
#11
JOURNAL ARTICLE
Aldo M Roccaro, Antonio Sacco, Jiantao Shi, Marco Chiarini, Adriana Perilla-Glen, Salomon Manier, Siobhan Glavey, Yosra Aljawai, Yuji Mishima, Yawara Kawano, Michele Moschetta, Mick Correll, Ma Reina Improgo, Jennifer R Brown, Luisa Imberti, Giuseppe Rossi, Jorge J Castillo, Steven P Treon, Matthew L Freedman, Eliezer M Van Allen, Winston Hide, Elaine Hiller, Irene Rainville, Irene M Ghobrial
Familial aggregation of Waldenström macroglobulinemia (WM) cases, and the clustering of B-cell lymphoproliferative disorders among first-degree relatives of WM patients, has been reported. Nevertheless, the possible contribution of inherited susceptibility to familial WM remains unrevealed. We performed whole exome sequencing on germ line DNA obtained from 4 family members in which coinheritance for WM was documented in 3 of them, and screened additional independent 246 cases by using gene-specific mutation sequencing...
May 26, 2016: Blood
https://read.qxmd.com/read/26797804/positive-selection-and-high-sensitivity-test-for-myd88-mutations-using-locked-nucleic-acid
#12
JOURNAL ARTICLE
A Albitar, W Ma, I DeDios, J Estella, S Agersborg, M Albitar
INTRODUCTION: Detection of mutations in the myeloid differentiation primary response gene 88 (MYD88) has clinical implications on diagnosis and therapy, especially in patients with Waldenström's macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (IgM-MGUS). We describe a method that provides greatly increased sensitivity for detecting minority mutations in MYD88. METHODS: We used a locked nucleic acid oligonucleotide to block amplification of wild-type DNA during polymerase chain reaction (PCR)...
April 2016: International Journal of Laboratory Hematology
https://read.qxmd.com/read/24913704/acupuncture-with-manual-and-electrical-stimulation-for-labour-pain-a-longitudinal-randomised-controlled-trial
#13
RANDOMIZED CONTROLLED TRIAL
Linda Vixner, Erica Schytt, Elisabet Stener-Victorin, Ulla Waldenström, Hans Pettersson, Lena B Mårtensson
BACKGROUND: Acupuncture is commonly used to reduce pain during labour despite contradictory results. The aim of this study is to evaluate the effectiveness of acupuncture with manual stimulation and acupuncture with combined manual and electrical stimulation (electro-acupuncture) compared with standard care in reducing labour pain. Our hypothesis was that both acupuncture stimulation techniques were more effective than standard care, and that electro-acupuncture was most effective. METHODS: A longitudinal randomised controlled trial...
June 9, 2014: BMC Complementary and Alternative Medicine
https://read.qxmd.com/read/23355206/nuclear-protein-dysregulation-in-lymphoplasmacytic-lymphoma-waldenstrom-macroglobulinemia
#14
JOURNAL ARTICLE
Mark J Roberts, Amy Chadburn, Shuo Ma, Elizabeth Hyjek, LoAnn C Peterson
Waldenström macroglobulinemia (WM) is characterized by monoclonal gammopathy, usually IgM, in association with lymphoplasmacytic lymphoma (LPL). Little is known of the expression of nuclear proteins involved in B-cell development in LPL/WM. In this study, the expression patterns of PAX5/BSAP, MUM1/IRF4, and PRDM1/BLIMP1 were analyzed in plasma cells and lymphocytes in 29 cases of newly diagnosed LPL/WM by double immunohistochemical staining with CD138 and CD22. These patterns were compared with the expression profiles seen in normal bone marrow samples, reactive tonsils, and cases of plasma cell myeloma and marginal zone lymphoma...
February 2013: American Journal of Clinical Pathology
https://read.qxmd.com/read/21200430/growth-factor-pdgf-bb-stimulates-cultured-cardiomyocytes-to-synthesize-the-extracellular-matrix-component-hyaluronan
#15
JOURNAL ARTICLE
Urban Hellman, Linus Malm, Li-Ping Ma, Göran Larsson, Stellan Mörner, Michael Fu, Anna Engström-Laurent, Anders Waldenström
BACKGROUND: Hyaluronan (HA) is a glycosaminoglycan located in the interstitial space which is essential for both structural and cell regulatory functions in connective tissue. We have previously shown that HA synthesis is up-regulated in a rat model of experimental cardiac hypertrophy and that cardiac tissue utilizes two different HA synthases in the hypertrophic process. Cardiomyocytes and fibroblasts are two major cell types in heart tissue. The fibroblasts are known to produce HA, but it has been unclear if cardiomyocytes share the same feature, and whether or not the different HA synthases are activated in the different cell types...
December 21, 2010: PloS One
https://read.qxmd.com/read/16263577/the-significance-of-carboxy-terminal-telopeptide-of-type-i-collagen-ictp-and-osteocalcin-oc-in-assessment-of-bone-disease-in-patients-with-multiple-myeloma
#16
JOURNAL ARTICLE
M Kuliszkiewicz-Janus, R Małecki, A Zółtaszek, M Zastawny
Bone disease occurring in multiple myeloma is usually evaluated using radiological methods. These methods, however, provide not much information about the dynamic process of bone resorption and formation. This study analysed levels of serum markers of bone turnover (ICTP and OC), reflecting function of osteoclasts and osteoblasts. It demonstrates increased level of ICTP in 75 patients with MM compared to control group (8 persons) and patients with Waldenström's macroglobulinemia (10 persons). The level of ICTP was also higher in patients with more advanced bone disease and probably in higher stage of disease according to Salmon and Durie classification...
December 2005: Leukemia & Lymphoma
https://read.qxmd.com/read/15781640/dehydroepiandrosterone-can-inhibit-the-proliferation-of-myeloma-cells-and-the-interleukin-6-production-of-bone-marrow-mononuclear-cells-from-patients-with-myeloma
#17
JOURNAL ARTICLE
Shangqin Liu, Hideaki Ishikawa, Fu-Jun Li, Zi Ma, Ken-ichiro Otsuyama, Hideki Asaoku, Saeid Abroun, Xu Zheng, Naohiro Tsuyama, Masanori Obata, Michio M Kawano
The serum levels of an adrenal sex hormone, dehydroepiandrosterone sulfate (DHEA-S), are significantly more decreased in human myelomas compared with the reduction brought by physiologic decline with age. In order to clarify the effect of DHEA on myeloma cells, we investigated whether DHEA and DHEA-S could inhibit interleukin-6 (IL-6) production of bone marrow mononuclear cells and the proliferation of myeloma cells from patients with myeloma. DHEA-S and DHEA suppressed IL-6 production from a bone marrow stromal cell line, KM-102, as well as in bone marrow mononuclear cells from patients with myeloma...
March 15, 2005: Cancer Research
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.